Several pharmaceutical companies now switch their primary focus from generic prescription drugs to medical specialties.

Rose Prince

2018-10-15 09:33:00 Mon ET

Several pharmaceutical companies now switch their primary focus from generic prescription drugs to medical specialties such as cardiovascular medications and radioactive therapies. The pharmaceutical giants need to focus on specific medical market niches because the Trump administration urges these firms to reduce drug prices and medical costs in America. Pfizer, Merck, and Johnson & Johnson now plan to dramatically reduce headcounts in the next few years. In addition to Pfizer, Merck, Johnson & Johnson, Novartis now plans to cut jobs through early retirement plans and layoffs worldwide. The Swiss pharmaceutical firm Novartis also plans to acquire American cancer drugmaker Endocyte for $2 billion. This strategic move accords with the broader competitive landscape that induces pharmaceutical firms to specialize in new medications and therapies that exhibit low price elasticities of patient demand. In stark contrast to generic prescription drugs, the new therapies and medications require the productive use of medical tech advances and can thus become more effective in treating specific diseases.

In a recent tweet, President Trump condemns pharmaceutical firms such as Pfizer for raising the prices of about 40 prescription drugs. In response, Pfizer CEO Ian Read decides to defer these price hikes to assuage grave concerns about patient demand and consumer protection.

 


If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.

Blog+More

AYA finbuzz podcast offers fresh insights into the latest stock market topics, economic trends, and personal finance inspirations as of October 2019.

Daphne Basel

2019-10-31 13:38:00 Thursday ET

AYA finbuzz podcast offers fresh insights into the latest stock market topics, economic trends, and personal finance inspirations as of October 2019.

  AYA Analytica finbuzz podcast channel on YouTube October 2019 In this podcast, we discuss several topical issues as of October 2019: (1)

+See More

International trade, immigration, and elite-mass conflict

Jacob Miramar

2023-12-09 08:28:00 Saturday ET

International trade, immigration, and elite-mass conflict

International trade, immigration, and elite-mass conflict The elite model portrays public policy as a reflection of the interests and values of elites. I

+See More

Nobel Laureate Joseph Stiglitz maintains that globalization only works for a few elite groups.

Becky Berkman

2019-08-09 18:35:00 Friday ET

Nobel Laureate Joseph Stiglitz maintains that globalization only works for a few elite groups.

Nobel Laureate Joseph Stiglitz maintains that globalization only works for a few elite groups; whereas, the government should now reassert itself in terms o

+See More

Can the Chinese renminbi become the next dual global reserve currency in addition to the American dollar?

Daphne Basel

2020-08-01 07:28:00 Saturday ET

Can the Chinese renminbi become the next dual global reserve currency in addition to the American dollar?

Technological advances, geopolitical risks, and pandemic outbreaks cannot shake investor confidence in the American dollar as the global reserve currency.

+See More

The U.S. stock market delivers a hefty long-term average return of 11% per annum.

Peter Prince

2017-03-09 05:32:00 Thursday ET

The U.S. stock market delivers a hefty long-term average return of 11% per annum.

From 1927 to 2017, the U.S. stock market has delivered a hefty average return of about 11% per annum. The U.S. average stock market return is high in stark

+See More

Strategic managers envision lofty purposes to enjoy incremental consistent progress over time.

Jonah Whanau

2020-10-06 09:31:00 Tuesday ET

Strategic managers envision lofty purposes to enjoy incremental consistent progress over time.

Strategic managers envision lofty purposes to enjoy incremental consistent progress over time. Allison Rimm (2015)   The joy of strategy: a bu

+See More